Epoetin Alfa
drugOn this page
Also known as AbseamedBinocritEpoetin alfa hexalEpoetina alfaEpoetine alfaEprexErythropoietin alfaErythropoietin for bioassaysEPOETINE
Summary
Epoetin Alfa (CHEMBL1201565) is an approved protein targeting EPOR; indicated across 39 conditions including anemia and chronic kidney disease.
At a glance
- Status: Approved (max clinical phase 4)
- Modality: Protein
- Targets: 1 (EPOR)
- Indications: 39 conditions
- Clinical trials: 191
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL1201565 |
| Name | Epoetin Alfa |
| Type | Protein |
| Max phase | 4 |
Also known as: Abseamed, Binocrit, Epoetin alfa, Epoetin alfa hexal, Epoetina alfa, Epoetine alfa, Eprex, Erythropoietin alfa, Erythropoietin for bioassays, EPOETIN ALFA, EPOETINE
Targets
Targets
Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).
| Gene | Target | Action | pAffinity | Cancer dependency | UniProt |
|---|---|---|---|---|---|
| EPOR | Eythropoietin receptor | Agonist | 11.15 | 0.9% | P19235 |
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
Aggregated over 1 target gene(s): EPOR.
Top Reactome pathways
5 total, by targets touching each:
| Pathway | Targets | Genes |
|---|---|---|
| Signaling by Erythropoietin | 1 | EPOR |
| Erythropoietin activates Phosphoinositide-3-kinase (PI3K) | 1 | EPOR |
| Erythropoietin activates Phospholipase C gamma (PLCG) | 1 | EPOR |
| Erythropoietin activates STAT5 | 1 | EPOR |
| Erythropoietin activates RAS | 1 | EPOR |
Dominant GO biological processes
| GO term | Targets |
|---|---|
| signal transduction | 1 |
| brain development | 1 |
| heart development | 1 |
| erythropoietin-mediated signaling pathway | 1 |
| decidualization | 1 |
| cytokine-mediated signaling pathway | 1 |
| proteasome-mediated ubiquitin-dependent protein catabolic process | 1 |
Indications & clinical
Indications
39 indications (8 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| anemia | 4 | MONDO:0002280 | EFO:0004272 |
| chronic kidney disease | 4 | MONDO:0005300 | EFO:0003884 |
| myelodysplastic syndrome | 4 | MONDO:0018881 | EFO:0000198 |
| HIV infectious disease | 4 | MONDO:0005109 | EFO:0000764 |
| acute myeloid leukemia | 3 | MONDO:0018874 | EFO:0000222 |
| prostate carcinoma | 3 | MONDO:0005159 | EFO:0001663 |
| hepatitis C virus infection | 3 | MONDO:0005231 | EFO:0003047 |
| head and neck cancer | 3 | MONDO:0005627 | EFO:0006859 |
| cardiac arrest | 3 | MONDO:0000745 | EFO:0009492 |
| cervical adenocarcinoma | 3 | MONDO:0005153 | EFO:0001416 |
| breast neoplasm | 3 | MONDO:0021100 | MONDO:0007254 |
| lung neoplasm | 3 | MONDO:0021117 | MONDO:0008903 |
| brain injury | 3 | MONDO:0043510 | MONDO:0043510 |
| peritoneal neoplasm | 3 | MONDO:0006901 | EFO:1001100 |
| ovarian cancer | 3 | MONDO:0008170 | MONDO:0008170 |
| leukemia | 3 | MONDO:0005059 | EFO:0000565 |
| squamous cell carcinoma | 3 | MONDO:0005096 | EFO:0000707 |
| perinatal asphyxia | 3 | MONDO:0006663 | EFO:1000824 |
| myocardial infarction | 2 | MONDO:0005068 | EFO:0000612 |
| stroke disorder | 2 | MONDO:0005098 | EFO:0000712 |
| exocrine pancreatic carcinoma | 2 | MONDO:0005192 | EFO:0002618 |
| peripheral neuropathy | 2 | MONDO:0005244 | EFO:0003100 |
| beta thalassemia | 2 | MONDO:0019402 | Orphanet:848 |
| ST-elevation myocardial infarction | 2 | MONDO:0041656 | EFO:0008585 |
| neonatal anemia | 2 | MONDO:0001240 | MONDO:0001240 |
| coronary artery disorder | 2 | MONDO:0005010 | EFO:0001645 |
| Friedreich ataxia | 2 | MONDO:0100339 | MONDO:0100339 |
| neoplasm | 2 | MONDO:0005070 | MONDO:0004992 |
| drug dependence | 1 | MONDO:0005303 | EFO:0003890 |
| sickle cell disease | 1 | MONDO:0011382 | MONDO:0011382 |
9 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.
Clinical trials
Total trials: 191.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE3 | 69 |
| PHASE2 | 59 |
| PHASE4 | 24 |
| Not specified | 20 |
| PHASE1 | 15 |
| PHASE2/PHASE3 | 3 |
| PHASE1/PHASE2 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT00022386 | PHASE4 | COMPLETED | Epoetin Alfa in Treating Chemotherapy-Related Anemia in Women With Stage I, Stage II, or Stage III Breast Cancer |
| NCT00211120 | PHASE4 | TERMINATED | Correction of Hemoglobin and Outcomes in Renal Insufficiency (CHOIR) |
| NCT00216541 | PHASE4 | COMPLETED | A Study of the Safety and Effectiveness of Epoetin Alfa on Hemoglobin Levels and Blood Transfusions in Cancer Patients Receiving Chemotherapy |
| NCT00283465 | PHASE4 | COMPLETED | A Study of the Effectiveness and Safety of Treatment With Epoetin Alfa on Hemoglobin Levels, Red Blood Cell Transfusions, and Quality of Life in Patients With Cancer Receiving Platinum-containing Chemotherapy |
| NCT00312871 | PHASE4 | TERMINATED | Effects of Early Correction of Anemia in Patients With Chronic Renal Insufficiency |
| NCT00315484 | PHASE4 | COMPLETED | Hematologic Response of Epoetin Alfa (PROCRIT) Versus Darbepoetin Alfa (ARANESP) in Chemotherapy Induced Anemia |
| NCT00317902 | PHASE4 | COMPLETED | An Open-Label Study to Evaluate the Effect of Every Other Week PROCRIT� (Epoetin Alfa) Dosing (40,000-60,000 Units) On Maintaining Quality of Life and Target Hemoglobin Levels in Anemic HIV-Infected Patients (CHAMPS II) |
| NCT00338000 | PHASE4 | COMPLETED | EPO-BUL-01 - Study of the Optimization of Anemia Management of EPREX (Epoetin Alfa) in Predialysis Patients With Chronic Renal Failure |
| NCT00338468 | PHASE4 | TERMINATED | A Study to Assess Disability in Anemic Elderly Patients With Kidney Disease Receiving PROCRIT (Epoetin Alfa) |
| NCT00350519 | PHASE4 | TERMINATED | The Safety and Effectiveness of PROCRIT (Epoetin Alfa) in Patients Undergoing Elective Major Abdominal and/or Pelvic Surgery |
| NCT00401869 | PHASE4 | COMPLETED | The Effect of PROCRIT (Epoetin Alfa) on Postoperative Vigor and Handgrip Strength (VIGOR Study) |
| NCT00425126 | PHASE4 | COMPLETED | Effect of Procrit (Epoetin Alfa) on Preventing Delayed Graft Function After Deceased Donor Renal Transplantation |
| NCT00495365 | PHASE4 | TERMINATED | A Dose Conversion Study of Epoetin Alfa in Subjects With the Anemia of Chronic Kidney Disease. |
| NCT00495378 | PHASE4 | TERMINATED | RAPID-2. A Study to Evaluate the Effectiveness of Alternate Dosing of PROCRIT (Epoetin Alfa) in Maintaining Hemoglobin Levels in Patients With Chemotherapy Related Anemia |
| NCT00524407 | PHASE4 | COMPLETED | Effect of Epoetin Alfa on Hemoglobin, Symptom Distress, and Quality of Life in Patients Receiving Chemotherapy |
| NCT00626574 | PHASE4 | TERMINATED | Treating Patients With Aneurysmal SubArachnoid Hemorrhage (SAH) With Epoetin Alfa |
| NCT00773513 | PHASE4 | COMPLETED | A Study to Assess All-Cause Mortality and Cardiovascular Morbidity in Participants With Chronic Kidney Disease (CKD) on Dialysis and Those Not on Renal Replacement Therapy Receiving Methoxy Polyethylene Glycol-Epoetin Beta (Mircera) or Reference Erythropoietin Stimulating Agents (ESAs) |
| NCT01374373 | PHASE4 | COMPLETED | Epoetin Alfa (Hemax®) Phase IV Study in Chemotherapy Induced Anemia |
| NCT01394991 | PHASE4 | COMPLETED | A Safety Study of Epoetin Alfa in Patients With Cancer Who Have Chemotherapy-Related Anemia |
| NCT01737879 | PHASE4 | TERMINATED | Evaluation of the Conversion From Peginesatide to Epoetin Alfa in Patients Receiving Hemodialysis |
| NCT02253654 | PHASE4 | COMPLETED | Evaluation of Two Epoetin Alfa Dosing Strategies in Subjects With Chronic Kidney Disease Receiving Hemodialysis |
| NCT02817555 | PHASE4 | COMPLETED | Cost Comparison Study of Darbepoetin Versus Epoetin Therapy to Treat Anemia in Hemodialysis Patients |
| NCT04134026 | PHASE4 | UNKNOWN | Evaluate the Efficacy and Safety of HIF-PHI for the Treatment of Anemia and Risks of Cardiovascular and Cerebrovascular Events in ESRD Newly Initiated Dialysis Patients |
| NCT05078138 | PHASE4 | COMPLETED | Impact of Erythropoietin on Hematological Adaptations and Physical Performance |
| NCT00843882 | PHASE3 | ACTIVE_NOT_RECRUITING | Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia |
| NCT03223961 | PHASE3 | ACTIVE_NOT_RECRUITING | A Trial Testing Early vs Late Onset of EPO Alfa Treatment in Lower Risk MDS |
| NCT03682536 | PHASE3 | ACTIVE_NOT_RECRUITING | A Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) Versus Epoetin Alfa for the Treatment of Anemia Due to IPSS-R Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Participants Who Require Red Blood Cell Transfusions and Are ESA Naïve |
| NCT04588311 | PHASE3 | RECRUITING | ErythroPOietin Alfa to Prevent Mortality and Reduce Severe Disability in Critically Ill TRAUMA Patients |
| NCT05949684 | PHASE3 | ACTIVE_NOT_RECRUITING | ELEMENT-MDS: A Study to Compare the Efficacy and Safety of Luspatercept in Participants With Myelodysplastic Syndrome (MDS) and Anemia Not Receiving Blood Transfusions |
| NCT07025681 | PHASE3 | RECRUITING | PK, PD, Safety and Immunogenicity Study of Erythropoietin of Incepta Pharmaceuticals Ltd With Eprex (Janssen-Cilag). |
| NCT07422480 | PHASE3 | RECRUITING | A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions |
| NCT00003341 | PHASE3 | COMPLETED | Epoetin Alfa in Treating Anemia in Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Multiple Myeloma and Anemia Caused By Chemotherapy |
| NCT00003600 | PHASE3 | COMPLETED | Epoetin Alfa in Treating Anemia in Patients Who Are Receiving Chemotherapy |
| NCT00004917 | PHASE3 | COMPLETED | Radiation Therapy With or Without Epoetin Alfa in Treating Anemic Patients With Head and Neck Cancer |
| NCT00014222 | PHASE3 | COMPLETED | Combination Chemotherapy With or Without Colony-stimulating Factors in Treating Women With Breast Cancer |
| NCT00017004 | PHASE3 | COMPLETED | Radiation Therapy and Cisplatin With or Without Epoetin Alfa in Treating Patients With Cervical Cancer and Anemia |
| NCT00017277 | PHASE3 | TERMINATED | Radiation Therapy With or Without Epoetin Alfa in Treating Patients With Head and Neck Cancer |
| NCT00028938 | PHASE3 | COMPLETED | Chemotherapy and Radiation Therapy With or Without Epoetin Alfa in Treating Patients With Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer |
| NCT00036400 | PHASE3 | COMPLETED | Study of the Efficacy and Safety of Epoetin Alfa Administered Weekly in Patients With Gastric or Rectal Cancers Undergoing a Treatment Plan of Preoperative Chemotherapy and Radiation Therapy, Followed by Surgery |
| NCT00058331 | PHASE3 | COMPLETED | Epoetin Alfa in Treating Anemia in Patients With Solid Tumors |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).
Related Atlas pages
- Genes: EPOR
- Diseases: anemia, chronic kidney disease, myelodysplastic syndrome, HIV infectious disease, acute myeloid leukemia, prostate carcinoma, hepatitis C virus infection, head and neck cancer, cardiac arrest, cervical adenocarcinoma, breast neoplasm, lung neoplasm, brain injury, peritoneal neoplasm, ovarian cancer, leukemia, squamous cell carcinoma, perinatal asphyxia